© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
April 04, 2021
Research presented at the 2021 Cholangiocarcinoma Foundation Annual Meeting focused on precision medicine and therapeutic targets.
April 02, 2021
At the 2021 Cholangiocarcinoma Foundation Annual Conference, experts discussed clinical trials in cholangiocarcinoma and the ways in which clinical trials overall can be made more available to patients.
Michael I. D'Angelica, MD, FACS, of Memorial Sloan Kettering Cancer Center, gives insight on genomic testing and its growing role in cholangiocarcinoma.
Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, discusses some of the key aspects of successful trials.
Last year, pemigatinib, the first targeted therapy in cholangiocarcinoma was approved for previously treated patients with FGFR2 fusions or rearrangements.
April 01, 2021
At the 2021 Cholangiocarcinoma Foundation Annual Conference, experts discussed guidelines and real-world data for the management of urgent symptoms in patients with cholangiocarcinoma who have biliary stents or drains.
Funda Meric-Bernstam, MD, co-chair of the 2021 Cholangiocarcinoma Foundation Annual Conference, gives her insight on immunotherapies in cholangiocarcinoma.
Michael I. D'Angelica, MD, FACS, of Memorial Sloan Kettering Cancer Center, discusses multidisciplinary care and why it is so important in hepatobiliary cancers.
On the first day of the Cholangiocarcinoma Foundation Annual Meeting, Elli Brimble, MS, MSc, Ciitizen’s head of Clinical Operations, offered insights from an ongoing study based on data provided by patients.
March 31, 2021
Discussions at the start of the 2021 Annual Cholangiocarcinoma Foundation Conference centered on challenges and advances made during the COVID-19 pandemic, and the potential of liver transplantation in cholangiocarcinoma.